Xtandi (enzalutamide) has been approved by the FDA for use in three different forms of advanced prostate cancer.

The prostate is a gland that men have. It produces some of the fluid that makes up semen and sits in front of the seminal vesicles, which make most of the seminal fluid.

The prostate gland is found below the bladder and in front of the rectum. Running through the middle of the prostate gland is the tube (urethra) that carries urine and semen out of the body.

Xtandi is an androgen receptor inhibitor. Androgens are a group of hormones that includes testosterone, which can stimulate prostate cancer cells to grow.

A number of types of cancer can develop in the prostate, but adenocarcinomas are by far the most common type.

What are 3 forms of advanced prostate cancer Xtandi is used for?

1. Non-metastatic castration-resistant prostate cancer (nmCRP)
   This is a type of advanced prostate cancer that has not spread (metastasized) to other parts of the body, but which is no longer responding to therapies designed to lower testosterone, such as hormone therapy or surgery.
2. Metastatic castration-resistant prostate cancer (mCRPC)
   This is a type of advanced prostate cancer that has spread to other parts of the body and is no longer responding to therapies designed to lower testosterone, such as hormone therapy or surgery.
3. Metastatic castration-sensitive prostate cancer (mCSPC)
   This is a type of advanced prostate cancer that has spread to other parts of the body, but still responds to therapies designed to lower testosterone, such as hormone therapy or surgery.

Xtandi comes in the form of a capsule or a tablet and is taken once a day.